Skip to main content

Table 1 Information of BCR-ABL1 TKIs

From: Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: a safety analysis of the FDA adverse event reporting system

Generic name

Brand name

Approval date

Indications

Imatinib

Gleevec

2001.05.10

CML, ALL, MDS, MPD, ASM, HES, CEL, DFSP, GIST

Dasatinib

Sprycel

2006.06.28

CML, ALL

Nilotinib

Tasigna

2007.10.29

CML

Bosutinib

Bosulif

2012.09.04

CML

Ponatinib

Iclusig

2012.12.14

CML, ALL

  1. ALL, acute lymphoblastic leukemia; MDS, myelodysplastic diseases; MPD, myeloproliferative diseases; ASM, aggressive systemic mastocytosis; HES, hypereosinophilic syndrome; CEL, chronic eosinophilic leukemia; DFSP, dermatofibrosarcoma protuberans; GIST, gastrointestinal stromal tumors
Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us